Table 1 Demographic and clinical characteristics of patients at the time of biopsy collection
Patients | Subset | Age (years) | Gender (M/F) | Disease duration (years) | Autoantibody | mRSS | Organ involvement | Therapy |
|---|---|---|---|---|---|---|---|---|
1 | LcSSc | 57 | F | 12 | Anti-Cenp-B | 17 | Lung (ILD), digital ulcers | ERAs, prednisone |
2 | LcSSc | 62 | F | 5 | Anti-Cenp-B | 4 | Esophagus | Ca2+ antagonists, PPIs |
3 | LcSSc | 70 | M | 9 | Anti-Cenp-B | 14 | Lung (ILD), esophagus | ERAs, PPIs, MMF |
4 | LcSSc | 67 | F | 10 | Anti-Cenp-B | 5 | Esophagus | Ca2+ antagonists, PPIs |
5 | LcSSc | 48 | F | 8 | Anti-Cenp-B | 14 | Lung (ILD) | ERAs, Prednisone, MMF |
6 | LcSSc | 55 | F | 11 | Anti-Cenp-B | 7 | Lung (ILD) | ERAs, Prednisone |
7 | LcSSc | 58 | F | 13 | Anti-Cenp-B | 17 | Lung (ILD), esophagus | ERAs, PPIs, MMF |
8 | LcSSc | 44 | F | 2 | Anti-Cenp-B | 7 | Lung (PAH), esophagus | Ca2+ antagonists, PPIs, prostanoids |
9 | LcSSc | 66 | F | 7 | Anti-Cenp-B | 14 | Digital ulcers esophagus | ERAs, PPIs |
10 | LcSSc | 60 | F | 9 | Anti-Cenp-B | 5 | Esophagus | Ca2+ antagonists, PPIs |
11 | DcSSc | 51 | F | 12 | Anti-Topo-I | 7 | Lung (PAH), digital ulcers | Ca2+ antagonists, ERAs, prostanoids |
12 | DcSSc | 72 | M | 11 | Anti-Topo-I | 17 | Lung (PAH), digital ulcers | ERAs, prostanoids, MMF |
13 | DcSSc | 64 | F | 7 | Anti-Topo-I | 17 | Lung (PAH), digital ulcers | ERAs, prostanoids, MMF |
14 | DcSSc | 63 | M | 13 | Anti-Topo-I | 12 | Lung (ILD) | ERAs, prednisone, MMF |
15 | DcSSc | 50 | F | 6 | Anti-Topo-I | 9 | Lung (ILD), esophagus | Ca2+ antagonists, PPIs |
16 | DcSSc | 68 | F | 15 | Anti-Topo-I | 14 | Lung (ILD) | ERAs, prednisone, MMF |
17 | DcSSc | 59 | F | 14 | Anti-Topo-I | 17 | Esophagus | Ca2+ antagonists, PPIs |
18 | DcSSc | 69 | M | 7 | Anti-Topo-I | 17 | Lung (PAH) | ERAs, prostanoids |
19 | DcSSc | 49 | F | 9 | Anti-Topo-I | 14 | Lung (PAH), esophagus | ERAs, prostanoids, PPIs |
20 | DcSSc | 61 | F | 11 | Anti-Topo-I | 17 | Lung (ILD), esophagus | Ca2+ antagonists, PPIs, MMF |